MRV Research

Pembrolizumab

Along with vemurafenib1, dabrafenib2 and trametinib3, pembrolizumab is approved for metastatic melanoma. Like ipilimumab4, it is an immune checkpoint inhibitor that works by modulating the patient’s own immune response to tumour cells.5

Read More

Veterans who served in the deserts of Afghanistan and Iraq have increased risk of skin cancer

Veterans who return home from the sun-baked Middle East have an increased chance of developing potentially deadly skin cancer, a study has concluded.

The new study, published in the Journal of Investigative Dermatology, found that many soldiers in Afghanistan and Iraq who spent much of their deployments outdoors weren’t adequately trained about the dangers of sun exposure and failed to use sunscreen regularly to help prevent melanoma.

Read More
MRV News
Melanoma News
Archive
Menu